Exploratory baseline mucosal transcriptomics and vedolizumab response in ulcerative colitis
- 1Department of Gastroenterology, The First Hospital of Tsinghua University, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Abstract
Currently, there are still no reliable pre-treatment biomarkers for vedolizumab in ulcerative colitis. To investigate baseline mucosal signals, we reconstructed the discovery cohort from GSE73661 and evaluated the derived panel in the blood samples from GSE191328 and the independent mucosal RNA-seq cohorts from E-MTAB-7845. The reconstructed cohort comprised 24 baseline samples, including 14 composite responders and 10 non-responders. Through repeated LASSO variable selection, the study identified an exploratory gene set consisting of ZNF689, TPRXL, ZC3H10, and MRPL55. The selection procedure yielded a mean held-out AUC of 0.611 across 18 complete nested-validation repetitions; this does not independently validate the final gene set. When the fixed gene set was projected exploratorily, the AUC for 17 blood samples was 0.458 (95% CI 0.162–0.755), and the AUC for 27 independent UC mucosal samples was 0.534 (95% CI 0.293–0.775). The apparent AUC of this gene set on the discovery set was 1.000, and 500 full-process bootstrap analyses indicated that gene selection was unstable. Among the three targeted inflammatory panels, interferon-γ showed a directional difference that was not statistically significant (mean GSVA score difference −0.425; nominal P = 0.066; adjusted P = 0.197). Expression scales and clinical endpoints differed across cohorts. The above results describe post-selection separation within the discovery cohort and do not establish reproducible predictive performance, tissue specificity, or a definitive four-gene signature.
Related
- Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update.
- Baseline Hypozincemia Predicts Clinical Relapse in Patients with Ulcerative Colitis in Remission
- Machine learning predicts relapse after anti-TNF withdrawal in ulcerative colitis using rectal biopsy transcriptomics
- Associations between redox-related biomarkers and treatment response in patients with inflammatory bowel disease initiating infliximab or vedolizumab
- Baseline mucosal transcriptomic endotypes stratify healing capacity and biologic therapy outcomes in ulcerative colitis: an integrative multi-cohort study
BibTeX
@article{zhang2026exploratory,
title = {{Exploratory baseline mucosal transcriptomics and vedolizumab response in ulcerative colitis}},
author = {Liang Zhang and Jian Liu and Chenfei Liang and Qiang Han and Da Li and Yali Wang},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0361301},
url = {https://doi.org/10.1371/journal.pone.0361301},
note = {CC BY},
}
RIS
TY - JOUR
TI - Exploratory baseline mucosal transcriptomics and vedolizumab response in ulcerative colitis
AU - Liang Zhang
AU - Jian Liu
AU - Chenfei Liang
AU - Qiang Han
AU - Da Li
AU - Yali Wang
PY - 2026
DA - 2026/10/26
JO - PLOS One
DO - 10.1371/journal.pone.0361301
UR - https://doi.org/10.1371/journal.pone.0361301
AB - Currently, there are still no reliable pre-treatment biomarkers for vedolizumab in ulcerative colitis. To investigate baseline mucosal signals, we reconstructed the discovery cohort from GSE73661 and evaluated the derived panel in the blood samples from GSE191328 and the independent mucosal RNA-seq cohorts from E-MTAB-7845. The reconstructed cohort comprised 24 baseline samples, including 14 composite responders and 10 non-responders. Through repeated LASSO variable selection, the study identified an exploratory gene set consisting of ZNF689, TPRXL, ZC3H10, and MRPL55. The selection procedure yielded a mean held-out AUC of 0.611 across 18 complete nested-validation repetitions; this does not independently validate the final gene set. When the fixed gene set was projected exploratorily, the AUC for 17 blood samples was 0.458 (95% CI 0.162–0.755), and the AUC for 27 independent UC mucosal samples was 0.534 (95% CI 0.293–0.775). The apparent AUC of this gene set on the discovery set was 1.000, and 500 full-process bootstrap analyses indicated that gene selection was unstable. Among the three targeted inflammatory panels, interferon-γ showed a directional difference that was not statistically significant (mean GSVA score difference −0.425; nominal P = 0.066; adjusted P = 0.197). Expression scales and clinical endpoints differed across cohorts. The above results describe post-selection separation within the discovery cohort and do not establish reproducible predictive performance, tissue specificity, or a definitive four-gene signature.
SN - 1932-6203
ER -